FATE
Fate Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.48
+2.48%Aug 13, 2026, 14:46 UTC
Fate Therapeutics reported a Q2 2026 loss of $0.25 per share, beating the Zacks Consensus Estimate of a $0.28 loss and improving from a $0.29 loss a year earlier.
Source:Aug 13, 2026, 12:30 UTC
Fate Therapeutics dosed the first lupus nephritis patient in its Phase 2 potentially registrational trial RECLAIM-LN, utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy, with the patient treated as an outpatient with same-day discharge.
Jul 9, 2026, 12:30 UTC
Fate Therapeutics received FDA clearance of its Investigational New Drug application for the FT839 product candidate, a dual-CAR T cell targeting CD19 and CD38 for autoimmune disorders.
Source:Jun 15, 2026, 00:00 UTC
Fate Therapeutics Inc elected Robert S. Epstein, Karin Jooss, and Laura J. Hamill as Class I Directors effective June 12, 2026.